Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

  • There is currently no data for SNG

Holding(s) in Company

21 Oct 2020 09:45

RNS Number : 7807C
Synairgen plc
21 October 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Synairgen plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Bong Koh and Nimish Shah (as the voting members of VHCP Management II, LLC and VHCP Management III, LLC)

 

City and country of registered office (if applicable)

New York, NY, U.S.A.

4. Full name of shareholder(s) (if different from 3.)v

Name

See section 11 below

City and country of registered office (if applicable)

New York, NY, U.S.A.

5. Date on which the threshold was crossed or reachedvi:

19 October 2020

6. Date on which issuer notified (DD/MM/YYYY):

21 October 2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

4.64%

4.64%

164,910,914

Position of previous notification (if

applicable)

5.91%

5.91%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

ISIN: GB00B0381Z20

7,655,000

4.64%

SUBTOTAL 8. A

7,655,000

4.64%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Bong Koh and Nimish Shah (as the voting members of VHCP Management II, LLC and VHCP Management III, LLC)

4.64%

N/A

4.64%

Bong Koh and Nimish Shah (as the votingmembers of VHCP Management II, LLC)

 

N/A

N/A

N/A

VHCP Management II, LLC

 

N/A

N/A

N/A

Bong Koh and Nimish Shah (as the votingmembers of VHCP Management III, LLC)

 

N/A

N/A

N/A

VHCP Management III, LLC

 

N/A

N/A

N/A

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Bong Koh and Nimish Shah are the voting members of VHCP Management II, LLC and VHCP Management III, LLC.

 

VCHP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. and manager of VHCP Co-Investment Holdings II, LLC, each of which holds shares in Synairgen plc falling below the notifiable threshold.

 

VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and manager of VHCP Co-Investment Holdings III, LLC, each of which holds shares in Synairgen plc falling below the notifiable threshold.

 

All percentages are based on the notified current issued share capital of Synairgen plc of 164,910,914 ordinary shares.

 

 

 

Place of completion

New York, NY, U.S.A.

Date of completion

21 October 2020

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFIFVTIRLLFII
Date   Source Headline
3rd Jun 201911:52 amRNSResult of AGM
18th Apr 20199:20 amRNSDirectorate Change, Annual Report & Notice of AGM
5th Apr 201912:55 pmRNSGrant of Options
14th Mar 20197:00 amRNSPositive DSMC Review of Phase II Study for SNG001
25th Feb 20197:00 amRNSPreliminary results for the year ended 31 Dec 2018
17th Jan 20198:31 amRNSUpdate on LOXL2 programme with Pharmaxis
22nd Oct 201810:05 amRNSHolding(s) in Company
22nd Oct 20187:00 amRNSPart 2 start of Phase II COPD trial
16th Oct 20183:01 pmRNSHolding(s) in Company
15th Oct 20188:49 amRNSHolding(s) in Company
12th Oct 201811:05 amRNSResult of General Meeting
12th Oct 201810:29 amRNSResult of General Meeting
25th Sep 20185:56 pmRNSResult of Fundraise
25th Sep 20181:01 pmRNSProposed Fundraise to raise c.£2.9 million
25th Sep 20181:00 pmRNSHalf-year Report
28th Jun 20187:00 amRNSPositive SNG001 Biomarker Data in COPD Patients
26th Jun 20181:05 pmRNSHolding(s) in Company
22nd Jun 201811:42 amRNSResult of AGM
22nd Jun 20187:00 amRNSSynairgen Safety Data with SNG001 in COPD Patients
17th May 20187:00 amRNSPosting of Annual Report and Notice of AGM
16th Apr 20184:29 pmRNSHolding(s) in Company
6th Apr 201812:14 pmRNSGrant of Options
3rd Apr 20185:21 pmRNSHolding(s) in Company
15th Mar 20183:13 pmRNSIssue of Equity
15th Mar 20183:11 pmRNSHolding(s) in Company
15th Mar 20187:00 amRNSPreliminary results for year ended 31 Dec 2017
7th Feb 20187:00 amRNSSynairgen starts dosing in Phase II COPD study
14th Dec 20177:00 amRNSUpdate on LOXL2 Programme&Pharmaxis Collaboration
8th Nov 20174:31 pmRNSHolding(s) in Company
27th Sep 20177:00 amRNSInterim results for six months ended 30 June 2017
27th Sep 20177:00 amRNSData update and clinical plan for COPD
13th Sep 201712:44 pmRNSHolding(s) in Company
6th Sep 20177:00 amRNSLOXL2 Inhibitor Update.
28th Jun 201712:41 pmRNSResult of AGM
5th Jun 20177:00 amRNSPosting of Annual Report and Notice of AGM
17th May 20177:00 amRNSPreliminary Results
27th Apr 20177:00 amRNSAZD9412 Update
27th Mar 20177:00 amRNSHolding(s) in Company
13th Mar 20173:10 pmRNSHolding(s) in Company
10th Mar 20178:34 amRNSAdditional Positive Data in Lung Fibrosis
17th Jan 20172:46 pmRNSHolding(s) in Company
13th Oct 201610:44 amRNSHolding(s) in Company
12th Oct 20167:00 amRNSAZD9412 Clinical Trial Update
22nd Sep 20167:00 amRNSInterim results for six months ended 30 June 2016
8th Sep 20167:00 amRNSNotice of Interim Results
14th Jun 201612:00 pmRNSResult of AGM
17th May 20167:00 amRNSPosting of Annual Report and Notice of AGM
21st Apr 20162:14 pmRNSHolding(s) in Company
23rd Mar 20167:00 amRNSExercise of Options
22nd Mar 20167:00 amRNSPreliminary results for the year ended 31 Dec 2015

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.